Header Logo

Connection

Charles Specht to Recombinant Proteins

This is a "connection" page, showing publications Charles Specht has written about Recombinant Proteins.
Connection Strength

0.498
  1. Specht CA, Homan EJ, Lee CK, Mou Z, Gomez CL, Hester MM, Abraham A, Rus F, Ostroff GR, Levitz SM. Protection of Mice against Experimental Cryptococcosis by Synthesized Peptides Delivered in Glucan Particles. mBio. 2021 02 22; 13(1):e0336721.
    View in: PubMed
    Score: 0.156
  2. Hester MM, Lee CK, Abraham A, Khoshkenar P, Ostroff GR, Levitz SM, Specht CA. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2020 01 16; 38(3):620-626.
    View in: PubMed
    Score: 0.143
  3. Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P, Abraham A, Shen ZT, Lodge JK, Akalin A, Homan J, Ostroff GR, Levitz SM. Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio. 2017 11 28; 8(6).
    View in: PubMed
    Score: 0.125
  4. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis. 2007 Sep 01; 196(5):796-800.
    View in: PubMed
    Score: 0.061
  5. Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol. 2005 Dec 01; 175(11):7496-503.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.